Article
Long-term outcomes by clinical and molecular risk stratification in patients with medulloblastoma receiving risk-adapted therapy.
Med (New York, N.Y.) - 8 May 2026
Liu Hailong, Su Yu, Zhang Jiao, Chen Xuan, Deng Kaiwen, Chen Li, Feng Jin, Wu Xiaochong, Daniels Craig, Li Yanong, Zhang Jing, Zhao Yahui, Shi Yanfeng, Liu Fei, Feng Zhaoyang, Wang Dongyang, Han Dongming, Wang Wei, Wang Ming, Zhang Junping, Qi Xueling, Li Jiankang, Gong Jian, Liu Wei, Tian Yongji, Chen Rui, Jiang Tao, Taylor Michael D, Li Chunde, Tian Yu, Qiu Xiaoguang
Abstract excerpt
BACKGROUND: Risk stratification and radiotherapy optimization for medulloblastoma (MB) increasingly rely on molecular classification, yet large-scale, cross-regional, real-world evidence remains limited. METHODS: We assembled a global MB database (Chinese cohort: N = 729; international: N = 494). Overall survival (OS)/progression-free survival (PFS) and risk stratification were analyzed by integrating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.